Afadel 20 Tablet

Introduction

Afadel is a prescription medication that contains the active ingredient Afatinib dimaleate. It is available under the brand name Afadel. This medication is primarily used for the treatment of certain types of lung cancer.

Uses

Afadel is prescribed to patients with non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It is used as a targeted therapy to slow down or stop the growth of cancer cells and help improve the patient’s condition.

Dosage and Administration

The dosage and administration of Afadel should be determined by a healthcare professional based on individual patient factors. Follow the prescribed dosage instructions provided by your healthcare provider. The tablets are usually taken orally once a day, with or without food. Swallow the tablet whole with a glass of water, and do not crush, chew, or dissolve it.

Mechanism of Action

Afadel works by inhibiting the activity of certain proteins, including EGFR, which are involved in the growth and spread of cancer cells. By blocking these proteins, it helps to slow down or stop the growth of cancer cells, reducing the size of tumors and preventing their spread to other parts of the body.

Side Effects

Common side effects may include diarrhea, skin rash, nail problems, decreased appetite, and mouth sores. Inform your healthcare provider if these side effects become severe or persistent.

Serious side effects may occur in some patients and may include severe diarrhea, severe skin reactions, lung problems, liver problems, and eye problems. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Afadel may interact with other medications, including certain antibiotics, antifungal drugs, and medications that affect liver enzymes. Inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements.

Precautions

Before taking Afadel, inform your healthcare provider about any known allergies, medical conditions, or medications you are taking. This medication may not be suitable for everyone, and your healthcare provider will consider these factors before prescribing it to you.

Afadel should not be taken by pregnant women, as it may harm the developing fetus. Use effective contraception during treatment and for a certain period after stopping the medication. Breastfeeding should also be avoided while taking Afadel.

Storage

Afadel should be stored at room temperature, away from direct sunlight and moisture. Keep it out of reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take Afadel exactly as prescribed by your healthcare provider.
• If you miss a dose, take it as soon as you remember, unless it is close to the time for your next dose. Do not take a double dose to make up for a missed one.
• If you experience any unusual or persistent side effects, contact your healthcare provider.
• attend all scheduled appointments with your healthcare provider for regular check-ups and monitoring.
• Do not start or stop any other medications without consulting your healthcare provider, as they may interact with Afadel.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Mastocytosis – Treatment (NHS UK) [Accessed 7 Jun. 2024] (online) Available at:
• Giotrif 20 mg film-coated tablets (Health Professionals SmPC) Available at:
• Afatinib (Drugs.com) [Accessed 16 Jun. 2024] (online) Available at:
• Drugs Approved for Lung Cancer (National Cancer Institute) [Accessed 9 Jun. 2024] (online) Available at:
• Laskin J, Liu SV, Tolba K, Heining C, Schlenk RF, Cheema P, Cadranel J, Jones MR, Drilon A, Cseh A, Gyorffy S, Solca F, Duruisseaux M. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol. 2020 Dec;31(12):1693-1703. doi: 10.1016/j.annonc.2020.08.2335. Epub 2020 Sep 9. [Accessed 16 Jun. 2024] Available at: